Shanghai Fochon Pharmaceutical Co., Ltd.

Fochon Pharmaceuticals, Ltd.

Chinese Academy of Sciences

Chongqing Fochon Pharmaceutical Co., Ltd.

Fochon Biosciences, Ltd.

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Fochon Pharmaceutical Co., Ltd.

Xingdong Zhao

Weibo Wang

Haohan Tan

Xianlong Wang

Jing Sun

Yanxin Liu

Zuwen Zhou

Rui Tan

Lihua Jiang

Tongshuang Li

Zhifu Li

Ling Chen

Zhifang Chen

Qihong Liu

Weipeng Zhang

Hongbin Liu

Yue Rong

Qiang Tian

Huajie Zhang

Lijun Yang

Min Lin

Chengxi He

Bin Liu

Li Linghu

Zongyao Zou

Fanxin Zeng

Jian Ding

Meiyu Geng

Kai Ran

Shu Lin

Jing Ai

Xia Peng

Chuiliang Yu

Yunling Wang

Yuwei Gao

Bo Fang

Hailong Shi

Quan Yuan

Jiemin Fu

Linghua Meng

Tao Cheng

Hong Fu

Provided are certain Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Apoptosis-inducing agents

Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.

Macrocyclic compounds as TRK kinases inhibitors

Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds thereof, and use of these compounds in preparing drugs for inhibiting ROCK. 

Deuterated compounds as rock inhibitors

Provided are certain TRK inhibitors of formula (I): pharmaceutical compositions thereof, and methods of use thereof.

Substituted 2-azabicyclo[3.1.0]hexanes as TRK kinases inhibitors

Provided are certain IDO inhibitors or pharmaceutically acceptable salts thereof which can inhibit enzymatic activity of indoleamine 2,3-dioxygenase (IDO) and may be useful for the treatment of diseases and disorders mediated by IDO. In addition, pharmaceutical compositions thereof and methods of use thereof are also provided.

Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase

Bcl-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof are provided. In particular, Bcl-2 inhibitors of formula (I) are provided, wherein the variable groups are as defined in the specification. The Bcl-2 inhibitors can be used to treat cell proliferative disorders. 

Compounds as BLC-2-selective apoptosis-inducing agents

Provided are certain URAT1 inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Indolizine derivatives, composition and methods of use

Certain CDK4/6 inhibitors and pharmaceutically acceptable salts thereof are described. In particular, these compounds can inhibit kinase activity of CDK4/6 and may be useful for the treatment of hyper-proliferative diseases like cancer and inflammation. In addition, the pharmaceutical compositions thereof and methods of use thereof are also described.

Certain protein kinase inhibitors

Provided are certain compounds or pharmaceutically acceptable salts thereof which can inhibit kinase activity of Bruton's tyrosine kinase (BTK) and may be useful for the treatment of diseases like cancer, immunological disease and inflammation.

Substituted pyrrolo[2,3-d]pyridazin-4-ones and pyrazolo[3,4-d]pyridazin-4-ones as protein kinase inhibitors

Provided are certain CDK4/6 inhibitors with the structure of formula (I), pharmaceutical compositions thereof, and methods of use therefor. The compounds are of the class of pyrimidin-2 amine derivatives, useful for the treatment of hyper-proliferative diseases. 

Certain protein kinase inhibitor

Provided are certain PI3K inhibitors, pharmaceutical compositions thereof, and methods of use therefor.

Provided are compound of formula (I) as certain CDK4/6 inhibitors, pharmaceutical compositions thereof, and methods of use thereof. 

Disclosed herein are protein kinase inhibitors, more particularly novel quinazoline derivatives and pharmaceutical compositions thereof, and method of use thereof.

Quinazoline derivatives, compositions thereof, and use as pharmaceuticals

Disclosed herein are protein kinase inhibitors, more particularly pyridazine derivatives and pharmaceutical compositions thereof, and method of use thereof.

Growing community of inventors

Chongqing, China

Xingdong Zhao